Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.48 -0.09 (-0.17%)

Streaming Delayed Price Updated: 3:59 PM EDT, Jun 5, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,066,807
Open	51.50
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	51.57
Today's Range	51.02 - 51.72
52wk Range	37.51 - 60.85
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting

June 02, 2026

From Genentech

Via Business Wire

Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

June 01, 2026

From Genentech

Via Business Wire

Performance

YTD	+0.1%	+0.1%
1 Month	+1.8%	+1.8%
3 Month	-5.8%	-5.8%
6 Month	+5.3%	+5.3%
1 Year	+26.0%	+26.0%

More News

President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks? ↗

May 26, 2026

Via The Motley Fool

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗

May 25, 2026

Via The Motley Fool

Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer

May 19, 2026

From Genentech

Via Business Wire

3 International ETFs for Investors Looking Beyond U.S. Stocks ↗

May 18, 2026

Via The Motley Fool

Eli Lilly Stock: Next Stop $2,000? ↗

May 18, 2026

Via The Motley Fool

Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026

April 30, 2026

From Genentech

Via Business Wire

Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign

April 24, 2026

From Genentech

Via Business Wire

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector

April 22, 2026

Via Investor Brand Network

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

April 22, 2026

From BioMedWire

Via GlobeNewswire

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

April 21, 2026

From Genentech

Via Business Wire

Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD

April 21, 2026

From Genentech

Via Business Wire

FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

April 21, 2026

From Genentech

Via Business Wire

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

Via The Motley Fool

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

Via Finterra

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

April 09, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology

April 06, 2026

Via MarketMinute

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

April 06, 2026

Via MarketMinute

The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets

April 03, 2026

Via MarketMinute

Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring

April 03, 2026

Via MarketMinute

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

April 03, 2026

Via Finterra

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

Via MarketMinute

The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)

April 02, 2026

Via Finterra

Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success

April 01, 2026

Via MarketMinute

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?

Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.

What exchange does Roche Holding AG Basel American Depositary Shares trade on?

Roche Holding AG Basel American Depositary Shares trades on the OTC Traded

What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?

The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded

What is the current price of Roche Holding AG Basel American Depositary Shares?

The current price of Roche Holding AG Basel American Depositary Shares is 51.48

When was Roche Holding AG Basel American Depositary Shares last traded?

The last trade of Roche Holding AG Basel American Depositary Shares was at 06/05/26 03:59 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.